Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 6/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 5/20 | 0.46 |
| ▸ | AXL | P30530 | 4/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14583914 | 1.00 | KMT2A (0.51) | KMT2AL3MBTL1KCNA5KLK7KLK5 | |
| SCHEMBL8280167 | 1.00 | KMT2A (0.51) | KMT2AL3MBTL1KCNA5KLK7KLK5 | |
| SCHEMBL1928743 | 1.00 | KMT2A (0.51) | KMT2AL3MBTL1KCNA5KLK7KLK5 | |
| SCHEMBL5645993 | 0.98 | KMT2A (0.54) | KMT2AL3MBTL1KCNA5KLK7KLK5 | |
| SCHEMBL5435734 | 0.98 | KMT2A (0.54) | KMT2AL3MBTL1KCNA5KLK7KLK5 | |
| SCHEMBL12734545 | 0.98 | KMT2A (0.54) | KMT2AL3MBTL1KCNA5KLK7KLK5 | |
| SCHEMBL4755871 | 0.93 | KLK7 (0.50) | KMT2AL3MBTL1KLK7KLK5PDE4B | |
| SCHEMBL31470310 | 0.87 | KMT2A (0.52) | KMT2AL3MBTL1KLK7KLK5KDM1A | |
| SCHEMBL24437025 | 0.86 | AXL (0.43) | KMT2AL3MBTL1KLK7KLK5MERTK | |
| SCHEMBL30861499 | 0.86 | CACNA1B (0.48) | KMT2AL3MBTL1KLK7KLK5MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306372-B1 | HETEROCYCLE DERIVATIVES AND DRUGS | NIPPON SHINYAKU CO LTD (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2035411-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-6794389-B2 | Quinazoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030119855-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1306372-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287695-A1 | Novel Compounds | OPRM1, OPRL1, OPRK1 | KMT2A 2880/4885L3MBTL1 1464/4885KCNA5 166/4885 |
| US-20030119855-A1 | Heterocycle derivatives and drugs | OPRL1, OPRK1, OPRD1 | KMT2A 2295/4885L3MBTL1 3670/4885KCNA5 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.